The One Health Stress Test: Global Biosecurity Lessons from 2025–2026

Introduction to Global Biosecurity and the “One Health” Protocol

The architecture of global health security is continuously tested by the emergence, re-emergence, and geographic expansion of biological threats. In the contemporary interconnected biosphere, biodefense and biosecurity represent critical pillars of national and regional security, transcending traditional military paradigms to encompass public health, agricultural stability, economic continuity, and ecological resilience. The years 2025 and 2026 have been characterized by a unique convergence of biological incidents. These events have been driven by climate-altered vector habitats, post-pandemic supply chain vulnerabilities, the rapid evolution of viral pathogens, and the intrinsic difficulties of maintaining human compliance in agricultural sanitation. From the unprecedented spillover of Highly Pathogenic Avian Influenza into dairy cattle in the United States, to the northern expansion of the Dengue vector in the European Alps, and the relentless persistence of African Swine Fever in Asia, regional defense frameworks have been stressed in entirely novel ways.

This research report provides an exhaustive comparative analysis of the biodefense and biosecurity programs in the United States, the European Union, and key Asian nations, specifically focusing on the People's Republic of China, Japan, and South Korea. By examining high-level legislative strategies alongside specific, recent biological events—such as the resurgence of the New World Screwworm, the spread of the Bluetongue virus, and the Mpox Clade Ib emergency—this analysis distills the structural strengths, bureaucratic vulnerabilities, and the cascading secondary effects of these regional frameworks. The overarching theoretical framework applied here relies on the "One Health" concept, an interdisciplinary approach that recognizes human, animal, and environmental health are intrinsically linked and must be governed through integrated, cross-sectoral strategies.

The United States: Heavily Resourced, Structurally Complex

The biodefense enterprise of the United States is characterized by massive federal investment, sophisticated technological capabilities, advanced research infrastructure, and a highly complex, often fragmented bureaucratic structure. The strategic vision of the nation is currently guided by the National Biodefense Strategy and Implementation Plan. Initially unveiled in September 2018 and comprehensively updated in October 2022, this strategy outlines a whole-of-government approach to address naturally occurring, deliberate, or accidental biological threats.¹ The framework requires the Secretaries of Defense, Health and Human Services (HHS), Homeland Security, and Agriculture to jointly assess and revise the strategy biennially, ensuring that policies, practices, and interagency agreements are continuously updated.²

Strategic Framework and Federal Funding Mechanisms

At the federal level, biodefense responsibilities are distributed across multiple agencies, creating a matrix of overlapping jurisdictions. Within HHS, the Administration for Strategic Preparedness and Response (ASPR) and the Biomedical Advanced Research and Development Authority (BARDA) play leading roles in the development, procurement, and stockpiling of medical countermeasures.³ The fiscal year 2025 President's Budget proposed a mandatory funding allocation of USD 10.54 billion to strengthen ASPR activities.³ This massive capital injection is designated for pandemic preparedness, the advanced research and development of vaccines, therapeutics, and diagnostics for high-priority pathogens, and the scaling up of domestic manufacturing capacity.³

A specific focal point of the recent U.S. strategy is the reduction of supply chain vulnerabilities exposed during previous pandemics. The 2025 budget earmarked USD 95 million specifically for the Biodefense Production of Medical Countermeasures and Essential Medicines, aligning directly with the legislative goals of the Make PPE in America Act.³ This funding aims to onshore the production of active pharmaceutical ingredients and personal protective equipment, ensuring that the strategic national stockpile is not entirely dependent on foreign manufacturing.⁴ Simultaneously, the Department of Agriculture (USDA) received requests from scientific bodies, such as the American Society for Microbiology, to increase funding for the Agriculture and Food Research Initiative to at least USD 500 million in fiscal year 2027 to support critical biodefense work against antimicrobial-resistant infections and transboundary animal diseases.⁵

Despite these vast financial resources, independent assessments highlight persistent structural flaws. The Bipartisan Commission on Biodefense noted in its 2024 blueprint that while the United States now possesses a national strategic plan and an estimate of federal expenditures, there is still no centralized, single position in the Executive Branch sufficiently empowered to lead the entirety of the biodefense enterprise.⁶ The history of U.S. biodefense is rooted in its offensive biological warfare program that ran from 1943 to 1969.⁶ Since the termination of that program, defensive responsibilities have been compartmentalized. This fragmentation becomes acutely evident during rapid-onset agricultural and zoonotic crises, where jurisdiction overlaps between human health agencies, such as the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA), and agricultural authorities within the USDA.

To provide a clear overview of the U.S. funding priorities directed toward biodefense and preparedness for the 2025 fiscal period, the following data summarizes the critical allocations within the ASPR budget.

Federal Agency / Department	Funding Category / Initiative	Proposed FY 2025 Allocation (USD)	Strategic Objective
HHS / ASPR	Mandatory Pandemic Preparedness	10.54 Billion	Vaccine development, diagnostics, domestic manufacturing scale-up, and biosurveillance.3
HHS / BARDA	Advanced Research and Development	970 Million	Next-generation countermeasure technologies and platform development.3
HHS / ASPR	Strategic National Stockpile	970 Million	Sustainment of critical medical supplies and emergency response logistics.3
HHS / ASPR	Biodefense Production of MCMs	95 Million	Onshoring essential medicines and PPE, fulfilling the Make PPE in America Act.3
USDA / FAS	Salaries and Expenses (Biodefense)	222 Million	Support for food and agriculture sector resilience and homeland security coordination.7

Case Study: The 2025-2026 New World Screwworm Resurgence

A primary example of the U.S. agricultural biodefense apparatus in action is the highly coordinated response to the 2025-2026 resurgence of the New World Screwworm (NWS), Cochliomyia hominivorax. The NWS is a devastating parasitic blowfly whose larvae obligately consume the healthy, living flesh of warm-blooded hosts, leading to severe myiasis, substantial morbidity, and often death if left untreated.⁸ Historically, the screwworm was endemic across the southern United States, causing an estimated USD 3.6 billion in annual economic losses to the livestock industry.⁸

The eradication of the NWS in the 20th century represents one of the greatest triumphs of biological control. Scientists Edward Knipling and Raymond Bushland pioneered the Sterile Insect Technique (SIT), an autocidal control method involving the mass-breeding of male flies, exposing them to ionizing radiation to render them infertile, and releasing them to mate with wild females.⁸ Because female NWS flies mate only once in their lifetime, copulation with a sterile male results in unfertilized eggs that never hatch, eventually collapsing the population.⁸ Following a successful 1954 trial on the island of Curacao, the U.S. and Mexico engaged in a massive eradication campaign from 1966 to 1972, eventually pushing the parasite down through Central America.⁸ By 2006, eradication efforts successfully established a permanent biological barrier at the Darien Gap in Panama, a dense rainforest that acts as a natural geographic choke point.⁸

However, biological containment is inherently vulnerable to logistical disruptions. The failure of the Darien Gap barrier provides a critical lesson in biosecurity fragility. In 2023, screwworm detections in Panama surged from a few dozen to thousands, overpowering the insect barrier.⁸ This breach was catalyzed by a combination of climate shifts, increased human migration through the Darien Gap, and crucial supply chain interruptions during the COVID-19 pandemic.⁸ The pandemic confinement disrupted the delivery of materials required for sterile insect production and weakened the operability of critical animal health checkpoints across Central America.⁸

By late 2024 and early 2025, the infestation moved aggressively northward through Mexico.⁹ The U.S. biodefense system was placed on high alert. The CDC investigated a traveler-associated human case in Maryland in August 2025; while no local transmission was found, the USDA initiated targeted trapping within a 20-mile radius.⁸ Predictive models suggested the pest would breach the U.S. border by mid-2025, but advanced surveillance and cross-border SIT releases delayed the entry.⁸ Finally, on June 3, 2026, the USDA confirmed the first domestic NWS detection in over half a century in a three-week-old calf in Zavala County, Texas, with larvae identified in the animal's umbilical tissue.⁸

The immediate U.S. response demonstrated the power and complexity of its biodefense protocols. Following the NWS Response Playbook, the USDA established a Type 1 Focal Outbreak protocol, creating a 20-kilometer infested zone and a surrounding 20-kilometer adjacent surveillance zone with strict animal movement controls.⁸ The USDA accelerated the deployment of a new sterile fly dispersal facility at Moore Air Base in Edinburg, Texas, transitioning from a localized Mexican release program to a domestic defensive posture.⁸ This facility aims to expand production to a maximum capacity of 300 million sterile flies per week by 2027.⁸

Simultaneously, the FDA utilized its regulatory flexibility, issuing Emergency Use Authorizations (EUAs) to rapidly approve animal drugs.¹¹ In a cascade of authorizations beginning in late 2025, the FDA cleared lotilaner for dogs and cats, ivermectin injectables, F10 antiseptic sprays, and an expanded EUA for doramectin injection covering dairy cattle, swine, sheep, and horses.¹¹ This established a novel pharmacological defense layer that did not exist prior to the crisis, illustrating how regulatory agility is a critical component of biodefense.

Case Study: H5N1 Avian Influenza Spillover into Dairy Cattle

Simultaneously, the United States has navigated a profound shift in viral epidemiology with the Highly Pathogenic Avian Influenza (HPAI) A(H5N1) virus. While traditionally confined to wild migratory birds and domestic poultry flocks, the spring of 2024 marked a sentinel event: the emergence and establishment of an H5N1 transmission cycle within U.S. dairy cattle herds, initially detected in Texas and North Carolina.¹² The virus caused widespread outbreaks in lactating bovines, presenting with clinical signs such as decreased milk production and thickened milk consistency.¹³

By the summer of 2026, the CDC had reported 71 human cases and two fatalities in the United States, almost exclusively among dairy and poultry workers who had direct occupational exposure to infected animals.¹² The interagency response heavily underscored the One Health approach, requiring seamless coordination between human public health, veterinary medicine, and agricultural economics. The USDA recognized that disease reporting relies heavily on the financial viability of the farmer; thus, they invested USD 1 billion in a comprehensive strategy to curb HPAI, which included direct financial assistance to dairy producers to enhance biosecurity and offset the costs of lost milk production and diagnostic testing.¹³

Concurrently, the FDA conducted continuous assessments of the commercial milk supply. Virological sampling indicated that infected cows shed massive quantities of the virus into their milk.¹⁵ However, the FDA successfully validated through rigorous silo studies that standard commercial pasteurization protocols are entirely effective at eliminating infectious H5N1 virus, thereby securing the human food supply chain.¹⁶ From a genomic perspective, continuous monitoring by the CDC and independent researchers provided a crucial measure of reassurance: despite the unprecedented mammalian transmission cycle, genetic sequencing indicated that the circulating H5N1 strains had not yet acquired the specific mammalian adaptation mutations necessary for sustained human-to-human airborne transmission.¹² The U.S. approach relies heavily on active, high-throughput surveillance networks and the rapid mobilization of financial compensation to ensure agricultural sector compliance, acting as a financial buffer to incentivize early reporting of outbreaks.

The European Union: Supranational Coordination and Public Health Focus

In stark contrast to the heavily militarized and financially decentralized U.S. model, the biosecurity framework of the European Union relies heavily on supranational coordination, emphasizing public health resilience, scientific risk assessment, and regulatory standard-setting across its Member States. Historically, defense planning and public health efforts in the EU have been deeply siloed.¹⁸ The COVID-19 pandemic served as a stark reminder that biological threats can be as disruptive as conventional military warfare, prompting a rapid evolution in EU policy rhetoric toward integrated biodefense.¹⁸

Institutional Evolution: HERA, ECDC, and EFSA

The creation of the Health Emergency Preparedness and Response Authority (HERA) represents a structural evolution in the EU's approach to biological threats. Operating within the European Commission, HERA's specific mandate is to ensure that the EU and its Member States are prepared to act swiftly in the face of cross-border health threats.¹⁹ HERA focuses heavily on the development, production, and procurement of medical countermeasures, addressing three primary threat categories: pathogens with pandemic potential, chemical, biological, radiological, and nuclear (CBRN) threats originating from accidental or deliberate release, and antimicrobial resistance (AMR).²⁰

HERA operates in concert with two other vital supranational bodies: the European Centre for Disease Prevention and Control (ECDC), which manages epidemiological intelligence and human health risk assessments, and the European Food Safety Authority (EFSA), which assesses risks in the agricultural, food, and animal health sectors.²¹ This triad ensures a coordinated One Health response. For example, during the global Mpox outbreak, HERA's intelligence gathering informed the ECDC's risk assessments, which in turn guided the European Medicines Agency (EMA) in regulatory support for relevant vaccines.²¹

However, a persistent structural challenge within the EU architecture is the disconnect between traditional military defense budgets and civilian biodefense funding. In the volatile geopolitical landscape of 2025 and 2026, defense spending across the continent surged. NATO allies committed to unprecedented budget targets, earmarking 3.5% of GDP for core defense requirements and 1.5% for resilience and critical infrastructure.¹⁸ Yet, biodefense often falls into a bureaucratic gray zone. It remains unclear whether civilian public health budgets, such as the EU4Health program, or military mechanisms, like the European Defence Fund (EDF), are ultimately responsible for funding high-impact biological countermeasures.¹⁸

To bridge this gap, HERA utilized the EU4Health Programme in September 2025 to launch action grants targeting specific vulnerabilities.²³ These grants prioritized the development of novel diagnostics for vector-borne diseases, medical countermeasures against CBRN agents, and the stockpiling of reusable personal protective equipment.²³ Furthermore, HERA expanded the EU FAB framework contracts—originally designed to ensure vaccine manufacturing readiness—to investigate the potential for expanding rapid manufacturing capabilities to cover PPE, laboratory reagents, and essential medicines through 2027.²⁴

Case Study: Climate-Driven Arboviral Expansion in Europe

The most pressing and geographically expansive biosecurity challenge in Europe during the 2025-2026 period has been the aggressive northward expansion of vector-borne diseases. This phenomenon is driven almost entirely by climatic changes.²⁵ Warmer ambient temperatures, milder winters that prevent vector die-off, and altered precipitation patterns have dramatically expanded the thermal niches suitable for arthropod vectors.²⁶

The Aedes albopictus mosquito, commonly known as the Asian tiger mosquito and a highly competent vector for Dengue, Zika, and Chikungunya viruses, exemplifies this threat. By June 2025, the ECDC reported that Aedes albopictus was firmly established in 369 regions across 16 European countries, an exponential increase from just 114 regions a decade prior.²⁶ The mosquito's ability to undergo diapause—a state of suspended development—allows it to survive temperate European winters, facilitating a steady northward migration.²⁵

In a sentinel event indicating shifting ecological baselines, the Dengue virus was detected in locally trapped mosquitoes north of the Alps in Switzerland for the first time in March 2026.²⁸ Furthermore, Europe recorded 27 distinct Chikungunya outbreaks in 2025, marking a new historical record for the continent.²⁶ The emergence of a locally acquired Chikungunya case in France's Alsace region—an exceptional occurrence at such a northern latitude—highlighted the expanding transmission risk.²⁶ Similarly, West Nile virus, transmitted primarily by Culex mosquitoes, saw its highest case numbers in three years, with novel infections reported in previously unaffected provinces in Italy and Romania.²⁶ The ECDC officially characterized this prolonged and intense transmission of mosquito-borne diseases as the "new normal" for Europe, necessitating updated vulnerability maps, intensive urban vector control protocols, and novel diagnostic platforms.²⁶

Case Study: The Bluetongue Virus Resurgence

In the agricultural sector, the European Union has battled severe, wide-ranging outbreaks of the Bluetongue virus (BTV). BTV is a noncontagious, arthropod-borne orbivirus transmitted by biting midges of the genus Culicoides.³⁰ The virus causes severe disease in domestic and wild ruminants, particularly sheep and cattle, characterized by fever, oral lesions, and high morbidity.³⁰

The 2025-2026 vector season saw a catastrophic resurgence of multiple BTV serotypes across the continent. BTV-3 spread explosively through Germany, the Netherlands, and France, causing severe clinical symptoms.³¹ In August 2025 alone, France reported over 1,104 confirmed outbreaks of BTV-3.³² Concurrently, two genetically distinct strains of BTV-8 circulated: an 'old' strain (BTV8-FRA2015) causing minor symptoms, and a 'new', highly virulent strain (BTV8-FRA2023) that spread from southern France through Switzerland, Italy, Austria, and into southern Germany.³¹

The economic and logistical impact of these outbreaks forced immediate regulatory action. The United Kingdom, managing complex import protocols post-Brexit, recorded 343 cases of BTV-3 in its 2025-2026 season.³³ To mitigate the risk of further incursions, the UK mandated that any cattle, sheep, or goats imported from affected regions must be vaccinated against BTV-3 prior to movement.³⁴ However, traditional live-attenuated and inactivated vaccines possess significant limitations, including the requirement for multiple doses and the inability to differentiate infected from vaccinated animals (DIVA).³⁰ Consequently, the European scientific response has pivoted toward the advanced evaluation of next-generation subunit formulations. These vaccines utilize specific viral proteins (VP2, VP5) combined with virus-like particles (VLPs) to provide strong humoral immunity while maintaining DIVA compatibility, a crucial feature that allows agricultural authorities to maintain international trade while actively controlling the virus.³⁰

Regarding the H5N1 avian influenza virus, Europe's exposure profile differs significantly from that of the United States. While the U.S. battles the virus in dairy cattle, EFSA assessed the risk of the specific U.S. bovine-adapted strain reaching Europe via trade as very low.³⁵ However, avian-adapted H5N1 continues to circulate heavily in wild birds across the continent. Following the detection of avian flu antibodies in a Dutch dairy cow in early 2026, the ECDC maintained its risk assessment but urged heightened vigilance.²² EFSA and ECDC continue to recommend rigorous biosecurity on poultry farms and targeted surveillance of humans in occupational contact with infected wildlife, publishing quarterly epidemiological reports to monitor for any genetic shifts in the virological characteristics of the circulating strains.¹⁴

To concisely compare the scale of vector-borne and transboundary diseases affecting Europe during this period, the following table details the primary pathogens, their respective vectors, and the affected geographic regions.

Pathogen / Disease	Primary Vector	Most Affected European Regions (2025-2026)	Biological Impact / Status
Dengue / Chikungunya	Aedes albopictus	France (Alsace), Italy, Switzerland (North of Alps)	Locally acquired transmission extending to novel northern latitudes.26
West Nile Virus	Culex species	Italy (Latina, Frosinone), Romania	Highest case numbers in three years; expansion into previously unaffected provinces.26
Bluetongue (BTV-3)	Culicoides midges	France, Germany, United Kingdom, Netherlands	Explosive spread causing severe clinical symptoms in ruminants; UK mandated import vaccinations.31
Bluetongue (BTV-8)	Culicoides midges	France, Italy, Switzerland, Austria	Circulation of a novel, highly virulent strain (FRA2023) distinct from older lineages.31
Avian Influenza (H5N1)	Wild avian reservoirs	Netherlands, general EU wild bird populations	Widespread avian circulation; isolated detection of antibodies in Dutch cattle.36

Asia: Stratified Governance and Point-of-Entry Defense

Biosecurity frameworks in Asia vary widely, reflecting diverse political systems, geographic constraints, and economic priorities. However, nations such as China, Japan, and South Korea share a common geographical vulnerability to transboundary animal diseases and zoonotic spillovers, leading to distinct, highly structured defense mechanisms that prioritize legal mandates, technological surveillance, and strict border controls.

China: Legislative Centralization and the "Four Beams" Architecture

In the wake of the SARS epidemic and the catastrophic economic impacts of the COVID-19 pandemic, the People's Republic of China undertook a massive, systemic overhaul of its biosecurity governance. Historically, China's biosecurity system evolved through three distinct phases. From 1949 to 2002, the nation built basic disease reporting and plant-quarantine systems that relied heavily on paper records.³⁸ From 2003 to 2019, following the SARS shock, China introduced internet-based surveillance, constructed high-containment BSL-3 and BSL-4 laboratories, and aligned its protocols with the WHO's International Health Regulations.³⁸ The modern era, beginning in 2020, saw the elevation of biosecurity to a core component of national security, culminating in the enactment of the comprehensive Biosecurity Law of the PRC on April 15, 2021.³⁸

The 2021 Biosecurity Law unifies previously fragmented regulations into a cohesive legal regime. It covers epidemic control for infectious diseases, biotechnology research applications, pathogenic laboratory management, the security of human genetic resources, and the prevention of bioterrorism.⁴¹ Furthermore, China strictly implements the Biological Weapons Convention through Amendment No.3 to its Criminal Law, penalizing the illegal manufacture, trade, or release of infectious pathogens.³⁹

Conceptually, Chinese biosecurity is modeled on a "Four Beams and Eight Pillars" architectural framework.³⁸ The "beams" represent the macro-level structures: strategic planning, the legal-policy framework, organizational management, and the cultural foundation.³⁸ The "pillars" represent the operational mechanisms necessary for execution, including risk monitoring, full-process risk management, technological innovation, international collaboration, inter-departmental coordination, public risk communication, and community-level prevention.³⁸

Despite this highly centralized legislative framework, operational realities present a complex picture. Academic analyses in 2026 highlight four persistent structural weaknesses within the Chinese system. First, strategic plans often lack actionable, artificial intelligence-enabled operational roadmaps for foresight.³⁸ Second, the legal framework, while broad, lacks clear accountability and dispute-resolution mechanisms.³⁸ Third, horizontal coordination is severely hampered by deep organizational silos among agricultural, health, military, and scientific agencies.³⁸ Finally, public compliance culture and professional training remain patchy at the grassroots level.³⁸ Consequently, while the top-down legal mandate is exceptionally strong, the lateral execution of biosecurity measures remains a vulnerability against novel pathogens or synthetic biology threats.

Japan: Zero-Tolerance Quarantine and Ecological Island Defense

Japan leverages its geography as an island nation to implement a strict, point-of-entry biosecurity model managed primarily by the Ministry of Agriculture, Forestry and Fisheries (MAFF).⁴⁵ Interestingly, Japanese law provides no statutory definition for the terms "biosafety" or "biosecurity".⁴⁶ Instead, the nation relies on a web of stringent, specific laws addressing plant protection, infectious disease control, and food safety.⁴⁶

Japan's defense against transboundary diseases, such as African Swine Fever and Highly Pathogenic Avian Influenza, is exceptionally rigid and unforgiving. To prevent the introduction of infectious livestock diseases, the importation of meat and meat products is strictly prohibited, with absolutely no exceptions allowed for personal souvenirs, in-flight meals, or small quantities.⁴⁵ The penalties for violating these import restrictions are severe, designed to act as an absolute deterrent. Illegal importation can result in imprisonment for up to three years or personal fines up to 3 million yen, while offending corporations can face fines up to 50 million yen.⁴⁵

During the peak holiday seasons in 2025 and 2026, as inbound tourism exceeded a staggering 40 million visitors, MAFF instituted extreme biosecurity measures at all airports and seaports.⁴⁷ These measures included mandatory shoe sole disinfection, enhanced international mail screening, and highly strengthened inspections of personal belongings.⁴⁷

The strictness of Japanese biosecurity is particularly evident in its protocols for importing live animals. Dogs and cats imported from non-designated regions must undergo microchip implanting, receive two rabies vaccinations, pass an antibody titer test, and complete a 180-day waiting period.⁴⁹ The technical specifications for microchips are rigorously enforced; they must comply with specific ISO standards containing a 15-digit code.⁴⁹ In 2025 and 2026, MAFF actively blocked microchips starting with specific identification numbers (e.g., 900202, 900113) due to validity investigations, and revoked the designation of an international laboratory, Biobest Laboratories Ltd., for violations of designation standards.⁴⁹ Japan's approach represents a highly effective defensive perimeter model, prioritizing the absolute exclusion of pathogens over the development of domestic mitigation or vaccination strategies.

South Korea: One Health Integration versus Behavioral Compliance

South Korea operates a sophisticated, technologically integrated biosecurity system that explicitly embraces the One Health model. The national framework is built upon the Second Master Plan for Preventing and Controlling Infectious Diseases (2018-2022) and the National Zoonotic Disease Management Plan.⁵¹ These frameworks mandate deep inter-ministerial collaboration between the Korea Disease Control and Prevention Agency (KDCA), which oversees human health, and the Ministry of Agriculture, Food and Rural Affairs (MAFRA), which oversees animal health.⁵¹

The South Korean system is highly digitized. The KDCA utilizes the Infectious Disease Integrated Management System, which is continuously linked to MAFRA's Korea Animal Health Integrated System (KAHIS) to share animal and human health data in real-time.⁵² Furthermore, the KDCA conducts frequent semiannual local government simulation exercises for zoonotic diseases to maintain field readiness and oversees the Antimicrobial Resistant Management Action Plan to prevent the spread of AMR pathogens.⁵²

However, the South Korean experience in the 2025-2026 period highlights a fundamental axiom of biosecurity: systemic technological resilience is inherently limited by individual human compliance. During the winter 2025-2026 avian influenza season, South Korea faced unprecedented outbreaks of three distinct highly pathogenic serotypes—H5N1, H5N6, and H5N9—across 53 poultry farms and numerous wild bird populations.⁵⁴ These outbreaks pointed to ongoing viral evolution and reassortment at the wildlife-poultry interface, a trend previously observed in long-term surveillance data from South Korea and Japan.⁵⁵

A watershed epidemiological investigation released by MAFRA in March 2026 revealed that the sophisticated national framework was being routinely bypassed at the ground level. The report found that a staggering 70 percent of the infected farms had at least one serious biosecurity violation.⁵⁴ The specific failures were systemic and behavioral: 70 percent of farms failed to require disinfection or protective clothing for individuals entering the premises; 68 percent failed to disinfect entering or exiting vehicles; 66 percent exhibited poor overall sanitation management; 62 percent of workers did not use farm-specific footwear; and 48 percent maintained inadequate physical barriers to prevent the entry of wild animals.⁵⁴

This data underscores a profound reality within biodefense: vast capital expenditures on surveillance technology and centralized data integration cannot offset the risks generated by basic sanitation and behavioral compliance failures at the agricultural interface.

The Regional Threat of African Swine Fever

A unifying threat across Asia, and extending into parts of Europe, is the relentless march of African Swine Fever (ASF). ASF is a highly contagious viral hemorrhagic disease caused by an Asfivirus. It is characterized by its extreme environmental stability and a case fatality rate approaching 100 percent in domestic pigs and wild boar.⁵⁷ The virus cannot be contained by traditional vaccines, as no universally effective, widely deployable vaccine currently exists, forcing nations to rely entirely on mass culling, strict movement restrictions, and stringent farm sanitation.

Between 2025 and 2026, ASF caused devastating economic losses across the Asian and Pacific regions.⁵⁷ In India’s Mizoram state, the virus caused the death of over 9,700 pigs in 2025 alone, affecting more than 12,500 pig-rearing families and resulting in cumulative financial losses exceeding USD 120 million since the disease was first detected in the region in 2021.⁵⁸ Bhutan recorded outbreaks specifically linked to the practice of swill feeding—feeding domestic pigs food scraps containing contaminated meat products—highlighting a critical pathway for viral introduction.⁵⁸ South Korea also noted a sharp increase in domestic pig outbreaks in early 2026, threatening large commercial operations.⁵⁸

In Europe, the ASF dynamic was primarily localized in the eastern member states, driven heavily by wild boar populations acting as a continuous reservoir. In 2025, EU Member States detected 585 ASF outbreaks in domestic pigs, a 76 percent increase compared to 2024.⁵⁹ Romania accounted for an overwhelming 81 percent of all EU outbreaks, primarily in establishments with fewer than 100 pigs, highlighting the vulnerability of small-holder operations.⁵⁹ Furthermore, epidemiological tracing in December 2025 observed an alarming ASF "jump" of approximately 30 kilometers from the nearest reported outbreak in Moldova, illustrating the virus's ability to spread rapidly via contaminated vehicles or human movement, bypassing localized containment zones.⁶⁰

The following table summarizes the key structural approaches and primary vulnerabilities of the Asian biosecurity frameworks analyzed.

Nation	Lead Authorities	Primary Structural Mechanism	Identified Vulnerabilities / Limitations
China	National People's Congress, Ministries of Health & Agriculture	Centralized legislation (2021 Biosecurity Law); "Four Beams, Eight Pillars" model.	Deep organizational silos; lack of lateral coordination; poor grassroots compliance culture.38
Japan	Ministry of Agriculture, Forestry and Fisheries (MAFF)	Absolute zero-tolerance border quarantine; extreme financial penalties for violations.	Total reliance on border exclusion; highly susceptible to undetected smuggling given massive tourist volume.45
South Korea	KDCA, MAFRA	One Health digital integration; linked human (KDCA) and animal (KAHIS) databases.	Severe behavioral non-compliance at the farm level; 70% of infected farms failed basic sanitation protocols.52

Global Flashpoints: The Mpox Clade Ib Emergency

While regional biodefense architectures focus heavily on agricultural threats and climate-driven vector expansion, the global community must simultaneously manage human-centric biological crises that test the limits of international coordination. The most prominent of these during the 2025-2026 period is the widespread epidemic of Mpox Clade Ib.

Mpox is caused by an orthopoxvirus closely related to the virus that causes smallpox. Clade I, endemic to the Congo Basin, has historically been associated with more severe disease and higher mortality rates than the Clade II virus that caused the global outbreak in 2022. The newly emerged Clade Ib represents a highly virulent strain that causes severe systemic illness, extensive mucosal and cutaneous lesions, and has demonstrated a concerning propensity for sustained human-to-human transmission.⁶¹

The World Health Organization declared a Public Health Emergency of International Concern (PHEIC) spanning from August 2024 through September 2025 as the virus expanded rapidly from the Democratic Republic of the Congo into previously unaffected neighboring countries, such as Burundi and Kenya.⁶¹ By March 2026, 30 countries in Africa had reported over 46,000 confirmed cases and 214 deaths, with Madagascar and the DRC bearing the brunt of the recent transmission.⁶³ Globally, since January 2024, the total case count exceeded 54,000, with nearly 500 fatalities.⁶²

The epidemiology of Clade Ib shifted significantly over the course of the outbreak. Initially characterized by zoonotic spillover and household transmission in Central Africa, the virus adapted to exploit new transmission networks. Beginning in the fall of 2025, several Western European countries began reporting Clade Ib cases among individuals who had no documented history of international travel, indicating that cryptic, localized transmission networks had become established, likely facilitated by sexual contact.⁶⁴ Concurrently, travel-associated cases were detected in the United States and linked back through genomic tracing to the African transmission zones, prompting localized public health interventions.⁶⁴

The Mpox emergency critically illustrates the limitations of regional biodefense systems when confronted with diseases featuring long incubation periods and diverse, intimate transmission routes. Despite the robust mechanisms of the EU's HERA and the U.S. ASPR, global vaccine inequity allowed the virus to establish a vast, uncontrolled reservoir in Central Africa.⁶³ This dynamic reinforces the principle that regional biosecurity is ultimately an illusion if global health security at the pathogen's point of origin remains unfunded, unsupported, and scientifically neglected.

Strategic Synthesis and Final Implications

A meticulous synthesis of the events, structural responses, and epidemiological data from the 2025-2026 period yields several critical, second-order insights regarding the trajectory of global biosecurity. These insights illuminate the limitations of current defense paradigms and suggest necessary evolutions for future policy.

First, climate change has irrevocably altered the geographic calculus of biodefense. Historically, defense architectures were designed to prevent the lateral movement of pathogens across national borders via trade or travel, treating geography as a static variable. However, the northward expansion of Aedes albopictus into the Swiss Alps and the explosion of the Bluetongue midge vector across the United Kingdom and France demonstrate that thermal gradients are shifting faster than regulatory frameworks can adapt. Similarly, the movement of the New World Screwworm through the Darien Gap into Texas was partially facilitated by changing environmental conditions that allowed the fly to establish new reproductive footholds. Consequently, biodefense must transition from a purely geographical border-defense model to a dynamic ecological management model, integrating climate forecasting, predictive modeling, and entomological surveillance directly into core national security protocols.

Second, the illusion of technological invulnerability is exposed by human behavioral factors. South Korea's biosecurity apparatus represents the pinnacle of digital integration, linking human health data with animal health data to create a seamless One Health surveillance net. Yet, the 2026 avian influenza outbreak exposed a fatal flaw: the entire system relies on physical biosecurity at the farm level. With 70 percent of infected farms failing basic sanitation protocols—such as wearing designated footwear or disinfecting vehicles—the technological superstructure was rendered effectively useless by human apathy, fatigue, or economic corner-cutting. This suggests that future biodefense investments must allocate significantly more capital toward the sociology of compliance, behavioral economics, and financial incentivization, rather than relying solely on advanced genomic tracking and data integration.

Third, the bifurcation of defense and health funding creates systemic blind spots. In the European Union, the rhetoric surrounding biodefense has increased, particularly in light of geopolitical volatility. NATO's mandate for 3.5 percent GDP defense spending marks a historic militarization effort. However, biological threats are largely agnostic to military deterrence. The lack of a clear funding pathway that bridges military CBRN readiness with civilian public health resilience creates a vulnerability where biological countermeasures are chronically underfunded compared to kinetic military assets. While the United States attempts to bridge this gap through massive mandatory HHS allocations, the actual execution remains divided across siloed agencies, lacking a singular, empowered executive leader.

Finally, the fragility of biological containment relies heavily on uninterrupted global supply chains. The resurgence of the New World Screwworm provides a perfect historical case study. The Panamanian biological barrier, a triumph of the Sterile Insect Technique, was held for decades. Its collapse in 2023 was directly linked to the logistical and supply chain disruptions caused by the COVID-19 pandemic, which interrupted the rearing and aerial dispersal of sterile flies. This highlights a profound vulnerability: active biological defense mechanisms, whether they rely on continuous sterile insect releases or the uninterrupted manufacturing of DIVA-compatible veterinary vaccines, require flawless logistical support. A disruption in global shipping, a localized kinetic conflict, or another pandemic can trigger a cascading failure, allowing suppressed agricultural or human pathogens to immediately rebound.

The global biodefense landscape of 2025 and 2026 clearly demonstrates that biological threats are becoming more complex, ecologically expansive, and economically devastating. The comparative analysis reveals diverse, yet universally strained, strategic architectures. To effectively navigate the remainder of the 21st century, national and regional biosecurity programs must deeply internalize the One Health philosophy, formally linking human epidemiology, veterinary medicine, and climate science within unified, well-funded command structures. A robust biodefense relies not only on the rapid development of novel countermeasures but equally on the resilience of the supply chains that deliver them and the sociopolitical trust that ensures their adoption at the ground level.

Works cited

1. National Biodefense Strategy: Combating Biological Threats & Enhancing Preparedness, accessed June 4, 2026, https://aspr.hhs.gov/biodefense/Pages/default.aspx

2. 6 USC 104: National biodefense strategy - OLRC Home, accessed June 4, 2026, https://uscode.house.gov/view.xhtml?req=(title:6%20section:104%20edition:prelim)

3. FY 2025 President's Request: ASPR Highlights, accessed June 4, 2026, https://aspr.hhs.gov/AboutASPR/BudgetandFunding/Pages/2025POTUS-budget-highlights.aspx

4. HHS ASPR Justification of Estimates for Appropriations Committee for Fiscal Year 2025, accessed June 4, 2026, https://aspr.hhs.gov/AboutASPR/BudgetandFunding/Documents/FY2025/ASPR-cj.pdf

5. ASM Encourages Increased Support of FY27 USDA Research, accessed June 4, 2026, https://asm.org/articles/policy/2026/april/asm-encourages-increased-support-of-fy27-usda-rese

6. BIODEFENSE IN CRISIS, accessed June 4, 2026, https://biodefensecommission.org/wp-content/uploads/2024/05/National-Blueprint-for-Biodefense-2024_final_.pdf

7. United States Department of Agriculture FY 2026 BUDGET SUMMARY - USDA, accessed June 4, 2026, https://www.usda.gov/sites/default/files/documents/2026-usda-budget-summary.pdf

8. USDA: USDA Confirms Presence of New World ... - Avian Flu Diary, accessed June 4, 2026, https://afludiary.blogspot.com/2026/06/usda-usda-confirms-presence-of-new.html

9. USDA Confirms First U.S. New World Screwworm Case Since 1966, Launches Major Response in South Texas, accessed June 4, 2026, https://www.americanagnetwork.com/2026/06/03/usda-confirms-first-u-s-new-world-screwworm-case-since-1966-launches-major-response-in-south-texas/

10. First U.S. screwworm case confirmed in South Texas, accessed June 4, 2026, https://www.texastribune.org/2026/06/03/new-world-screwworm-texas-reported-case/

11. New World screwworm confirmed in United States, USDA ... - DVM360, accessed June 4, 2026, https://www.dvm360.com/view/new-world-screwworm-confirmed-in-united-states-usda-announces

12. A(H5) Bird Flu: Current Situation - CDC, accessed June 4, 2026, https://www.cdc.gov/bird-flu/situation-summary/index.html

13. H5N1 Hpai – Resources & Guidance - usda aphis, accessed June 4, 2026, https://www.aphis.usda.gov/h5n1-hpai

14. Public health risk associated with HPAI H5N1 - EFSA, accessed June 4, 2026, https://www.efsa.europa.eu/sites/default/files/2024-07/5.4-public-health-risk-of-hpai-h5n1-virus.pdf

15. Avian flu confirmed in Texas, Idaho cows | CIDRAP, accessed June 4, 2026, https://www.cidrap.umn.edu/avian-influenza-bird-flu/avian-flu-confirmed-texas-idaho-cows

16. Investigation of Avian Influenza A (H5N1) Virus in Dairy Cattle | FDA, accessed June 4, 2026, https://www.fda.gov/food/alerts-advisories-safety-information/investigation-avian-influenza-h5n1-virus-dairy-cattle

17. Avian influenza virus type A (H5N1) in U.S. dairy cattle | American Veterinary Medical Association, accessed June 4, 2026, https://www.avma.org/resources-tools/animal-health-and-welfare/animal-health/avian-influenza/avian-influenza-virus-type-h5n1-us-dairy-cattle

18. Beyond the battlefield: Rethinking defence to integrate biological preparedness | Science, accessed June 4, 2026, https://sciencebusiness.net/events/beyond-battlefield-rethinking-defence-integrate-biological-preparedness

19. Health Emergency Preparedness and Response (HERA), accessed June 4, 2026, https://health.ec.europa.eu/health-emergency-preparedness-and-response-hera_en

20. Funding and opportunities - Public Health - European Commission, accessed June 4, 2026, https://health.ec.europa.eu/health-emergency-preparedness-and-response-hera/funding-and-opportunities_en

21. Preparing Europe for future health threats and crises – the European Health Emergency and Preparedness Authority; improving EU preparedness and response in the area of medical countermeasures - PMC, accessed June 4, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9693794/

22. Detection of avian flu antibodies in Dutch dairy cow: ECDC risk assessment remains unchanged, accessed June 4, 2026, https://www.ecdc.europa.eu/en/publications-data/detection-avian-flu-antibodies-dutch-dairy-cow-ecdc-risk-assessment-remains

23. Building Europe's Health Shield: New EU4Health Calls Advance Medical Countermeasures and Diagnostics - Global Biodefense, accessed June 4, 2026, https://globalbiodefense.com/2025/09/22/eu4health-2025-crisis-preparedness-medical-countermeasures/

24. EN EN ANNEX HERA work plan for 2025 - Public Health - European Commission, accessed June 4, 2026, https://health.ec.europa.eu/document/download/06895ccf-03d8-43b9-9c24-c4aa03c84b8a_en?filename=hera_c_2025_1851_annex_en.pdf

25. Aedes albopictus and dengue transmission risk in France over the 21st century - bioRxiv, accessed June 4, 2026, https://www.biorxiv.org/content/10.64898/2026.03.06.710080v1.full-text

26. World Mosquito Day 2025: Europe sets new records for mosquito-borne diseases - ECDC, accessed June 4, 2026, https://www.ecdc.europa.eu/en/news-events/world-mosquito-day-2025-europe-sets-new-records-mosquito-borne-diseases

27. Aedes albopictus - current known distribution: June 2025 - ECDC - European Union, accessed June 4, 2026, https://www.ecdc.europa.eu/en/publications-data/aedes-albopictus-current-known-distribution-june-2025

28. Dengue virus detected in mosquitoes in Switzerland (sample from 2024): First report of detection north of the Alps - BEACON, accessed June 4, 2026, https://beaconbio.org/en/report/?reportid=af8beb24-26ee-45e3-8293-fc3b81d0a6c4&eventid=b556864e-2573-48c6-8087-95f005c5838a

29. Europe Faces Multiple Arboviral Threats in 2025 - PMC - NIH, accessed June 4, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12737385/

30. Bluetongue in the Mediterranean Basin: An Overview of Recent Hotspots and Advances in Vaccine Technologies - PMC, accessed June 4, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12942964/

31. Bluetongue Disease | Friedrich-Loeffler-Institut, accessed June 4, 2026, https://www.fli.de/en/news/animal-disease-situation/bluetongue-disease/

32. Updated Outbreak Assessment #13 - Bluetongue Virus in Europe - GOV.UK, accessed June 4, 2026, https://assets.publishing.service.gov.uk/media/689eea3f2e8cc8ec5b3572be/BTV_Europe_Aug_2025.pdf

33. Bluetongue: latest situation - GOV.UK, accessed June 4, 2026, https://www.gov.uk/government/news/bluetongue-latest-situation

34. Bluetongue Disease - Isle of Man Government, accessed June 4, 2026, https://www.gov.im/categories/business-and-industries/agriculture/types-of-notifiable-diseases/bluetongue-disease/

35. EFSA: introduction of bird flu from US dairy cattle to Europe very unlikely, but vigilance urged, accessed June 4, 2026, https://www.efsa.europa.eu/en/news/efsa-introduction-bird-flu-us-dairy-cattle-europe-very-unlikely-vigilance-urged

36. ECDC Statement On H5N1 Antibodies in Dutch Dairy Cow: ECDC Risk Assessment Remains Unchanged - Avian Flu Diary, accessed June 4, 2026, https://afludiary.blogspot.com/2026/01/ecdc-statement-on-h5n1-antibodies-in.html

37. Avian influenza | EFSA - European Union, accessed June 4, 2026, https://www.efsa.europa.eu/en/topics/topic/avian-influenza

38. China's biosafety/biosecurity governance: evolution, challenges, and architecture, accessed June 4, 2026, https://www.eurekalert.org/news-releases/1111051

39. The Biological Weapons Convention_Ministry of Foreign Affairs of the People's Republic of China, accessed June 4, 2026, https://www.fmprc.gov.cn/eng/wjb/zzjg_663340/jks_665232/kjlc_665236/shwq_665244/202406/t20240606_11405160.html

40. China's Biosafety/Biosecurity Concept and, accessed June 4, 2026, http://www.cicir.ac.cn/UpFiles/file/20230630/6382374889951538716352930.pdf

41. China signs off on PRC Biosecurity Law: What this means for industry players in China, accessed June 4, 2026, https://www.dlapiper.com/insights/publications/2020/10/china-signs-off-on-prc-biosecurity-law-what-this-means-for-industry-players-in-china

42. China's new PRC Biosecurity Law, accessed June 4, 2026, https://www.simmons-simmons.com/en/publications/ckkz6vtxs14830a99h0xou5fo/china-s-new-prc-biosecurity-law

43. China's evolving biosafety/biosecurity legislations - PMC, accessed June 4, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8245076/

44. China - Biological Weapons Convention National Implementation Measures Database, accessed June 4, 2026, https://bwcimplementation.org/states/china

45. Thorough Implementation of Animal and Plant Quarantine Measures during the Golden Week Holiday | GraSPP - 東京大学, accessed June 4, 2026, https://www.pp.u-tokyo.ac.jp/en/student-bulletin/2026-04-27-55765/

46. Biosecurity Laws - Loc, accessed June 4, 2026, https://tile.loc.gov/storage-services/service/ll/llglrd/2024555213/2024555213.pdf

47. Animal and Plant Quarantine - Graduate School of Agricultural Science - Tohoku University, accessed June 4, 2026, https://www.agri.tohoku.ac.jp/en/news/animal-and-plant-quarantine/

48. Notice on Strengthened Animal and Plant Quarantine Measures during the Year-End, New Year Holidays and the Lunar New Year (MAFF) | Consular Office of Japan in Anchorage, accessed June 4, 2026, https://www.anchorage.us.emb-japan.go.jp/itpr_en/11_000001_00808.html

49. Import dogs and cats into Japan (from non-designated regions) - 農林水産省, accessed June 4, 2026, https://www.maff.go.jp/aqs/english/animal/dog/import-other.html

50. Import and export quarantine of dogs and cats - 農林水産省, accessed June 4, 2026, https://www.maff.go.jp/aqs/english/animal/dog/index.html

51. South Korea | GHS Index, accessed June 4, 2026, https://ghsindex.org/wp-content/uploads/2021/12/South-Korea.pdf

52. Effect of the establishment of the Korea Centers for Disease Control and Prevention/Korea Disease Control and Prevention Agency from the perspective of global health security - PMC, accessed June 4, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12047026/

53. Preventive Responses to Human Avian Influenza Infection in the Republic of Korea, 2023–2024, accessed June 4, 2026, https://eng.phwr.org/journal/view.html?pn=ahead&uid=1125&vmd=Full

54. South Korea: MAFRA Investigation Into Biosecurity Lapses on HPAI Affected Poultry Farms, accessed June 4, 2026, https://afludiary.blogspot.com/2026/03/south-korea-mafra-investigation-into.html

55. Endemic avian influenza landscape in Asia: sustained zoonotic risks - PMC, accessed June 4, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12864359/

56. Highly Pathogenic Avian Influenza Virus (H5N1) in Domestic Poultry and Relationship with Migratory Birds, South Korea - PMC, accessed June 4, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC2570817/

57. African swine fever (ASF) situation update in Asia & Pacific, accessed June 4, 2026, https://www.fao.org/animal-health/situation-updates/asf-in-asia-pacific/en

58. February Report 2026 - Swine Health Information Center, accessed June 4, 2026, https://www.swinehealth.org/wp-content/uploads/2026/02/February-Report-2026.pdf

59. African swine fever outbreaks increase in pigs and wild boar across the EU | EFSA, accessed June 4, 2026, https://www.efsa.europa.eu/en/news/african-swine-fever-outbreaks-increase-pigs-and-wild-boar-across-eu

60. Period covered: December 2025 - This report provides an update of the ASF situation, according to the information shared with WOAH., accessed June 4, 2026, https://www.woah.org/app/uploads/2026/01/asf-report-72-2.pdf

61. Mpox outbreak - World Health Organization (WHO), accessed June 4, 2026, https://www.who.int/emergencies/situations/mpox-outbreak

62. 2023–2026 mpox epidemic - Wikipedia, accessed June 4, 2026, https://en.wikipedia.org/wiki/2023%E2%80%932026_mpox_epidemic

63. Mpox: Multi-country External Situation Report no. 64, accessed June 4, 2026, https://cdn.who.int/media/docs/default-source/_sage-2026/multi-country-outbreak-of-mpox--external-situation-report_64.pdf

64. Monkeypox in the United States and Around the World: Current Situation - CDC, accessed June 4, 2026, https://www.cdc.gov/monkeypox/situation-summary/index.html

65. Epidemiological Update Mpox in the Americas Region - Pan American Health Organization, accessed June 4, 2026, https://www.paho.org/sites/default/files/2026/04/23042026epiupdatempoxenfinal.pdf